AstraZeneca PLC (NYSE: AZN) Q4 2022 earnings call dated Feb. 09, 2023 Corporate Participants: Andy Barnett -- Vice President Global Head of Investor Relations Pascal
AstraZeneca plc
-(AZN)
XNYS:AZN
AstraZeneca PLC (AZN) Q2 2022 Earnings Call Transcript
AstraZeneca PLC (NYSE: AZN) Q2 2022 earnings call dated Jul. 29, 2022 Corporate Participants: Andy Barnett -- Head of Investor Relations Pascal Soriot -- Executive Director
AstraZeneca PLC (AZN) Q1 2022 Earnings Call Transcript
AstraZeneca PLC (NYSE: AZN) Q1 2022 earnings call dated Apr. 29, 2022 Corporate Participants: Chris Sheldon -- Head of Investor Relations Pascal Soriot -- Executive Director
Earnings calendar for the week of April 26
Investor sentiment was hit by the government's proposal to levy higher capital gain tax on wealthy individuals, and the market shifted to
What’s happening on the COVID-19 front? Here are a few updates.
Right about this time last year, the COVID-19 pandemic took over the world with full force as several countries went into complete
AstraZeneca PLC (AZN) Q4 2020 Earnings Call Transcript
AstraZeneca PLC (NYSE: AZN) Q4 2020 earnings call dated Feb. 11, 2021 Corporate Participants: Pascal Soriot -- Chief Executive Officer David Fredrickson -- Executive Vice-President, Oncology
COVID-19 vaccine: These pharma companies have also made headway
The month of November has been huge for pharmaceutical companies with many submitting positive results from their clinical trials for the development
AstraZeneca stock looks a good bet as COVID antibody drug brings fresh hope
With the pandemic situation showing little signs of improvement, healthcare institutions are under pressure to expedite their vaccine development programs, amid growing
AstraZeneca PLC (AZN) Q2 2020 Earnings Call Transcript
AstraZeneca PLC (NYSE: AZN) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Pascal Soriot -- Executive Director and Chief Executive Officer Dave
AstraZeneca (NYSE: AZN): Q4 2019 Earnings Snapshot
-- AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share. -- Revenue
AstraZeneca (NYSE: AZN): Q3 2019 Earnings Snapshot
-- AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This
AstraZeneca’s Q2 results beat market expectations
AstraZeneca Plc (NYSE: AZN) topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a lift of
Cancer drugs boost AstraZeneca results in Q1
Riding on the strong demand for its cancer drugs, AstraZeneca Plc (NYSE: AZN) on Friday reported its third consecutive quarter of top
AstraZeneca drops 6% after announcing $6.9 billion cancer drug deal with Daiichi Sankyo
Shares of AstraZeneca Plc (NYSE: AZN) dropped about 6% on NYSE during the pre-market hours and continued to trade in the negative
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
Earnings: Oncology unit drives AstraZeneca topline higher in Q4
AstraZeneca Plc (AZN) reported a 22% dip in earnings for the fourth quarter to 82 cents per share, weighed down higher costs.
AstraZeneca Q3 profit dips 37% but beats estimates
AstraZeneca Plc (AZN) reported a 37% dip in earnings for the third quarter due to lower revenue, a decline in gross margin